Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14967165 | 0.72 | USP2 (0.34) | DGAT1GAAUSP2SMN1; SMN2CYP4F2 | |
| SCHEMBL16976214 | 0.71 | DGAT1 (0.35) | DGAT1CYP4F2CYP4A11 | |
| SCHEMBL9109275 | 0.68 | CYP4F2 (0.33) | USP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL6453825 | 0.68 | GAA (0.33) | GAAUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL14967585 | 0.68 | CYP4F2 (0.33) | USP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL6453831 | 0.68 | GAA (0.33) | GAAUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL26409713 | 0.67 | USP2 (0.37) | DGAT1GAAUSP2SMN1; SMN2 | |
| SCHEMBL20296707 | 0.67 | KMT2A (0.36) | DGAT1 | |
| SCHEMBL16837867 | 0.65 | DGAT1 (0.31) | DGAT1USP2SMN1; SMN2 | |
| SCHEMBL17801156 | 0.65 | USP2 (0.30) | USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
| EP-3150617-B1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | CIPLA USA INC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-9688711-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-3150617-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2016-12-22 | — | — | US | disclosed |
| EP-2217610-B1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9266919-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2015-02-12 | — | — | US | disclosed |
| US-8822424-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130217642-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8383596-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120214759-A1 | TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214760-A1 | TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2010132777-A2 | TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132770-A1 | TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2217610-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2009067692-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217642-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | DGAT1 3101/4885GAA 253/4885USP2 3805/4885 |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | DGAT1 3101/4885GAA 253/4885USP2 3805/4885 |
| US-20160368942-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | DGAT1 3101/4885GAA 253/4885USP2 3805/4885 |
| US-20120214760-A1 | TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | NPEPPS, PIGS, ATP6V1B1 | DGAT1 1268/4885GAA 36/4885USP2 2545/4885 |
| US-20150045317-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | DGAT1 3101/4885GAA 253/4885USP2 3805/4885 |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | DGAT1 3101/4885GAA 253/4885USP2 3805/4885 |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | MRPL21, MRPL9, NQO2 | DGAT1 3101/4885GAA 253/4885USP2 3805/4885 |
| US-20120214759-A1 | TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | PIGS, PIGO, NPEPPS | DGAT1 1153/4885GAA 64/4885USP2 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.